Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Respiratory
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Deal with Ono the first for Concordia's novel Ras inhibitor
02 September 2010
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer. The Japanese firm will pay undisclosed ...
Ranbaxy opens second plant in South Africa
01 September 2010
Ranbaxy Laboratories has opened its second manufacturing facility in South Africa at Roodepoort, Johannesburg, at an investment of $30 million. It will manufacture a range of products including analgesics, cold, cough and flu preparations, ...
Glenmark unveils details of its TRPA1 antagonist
31 August 2010
Glenmark Pharmaceuticals is developing a TRPA1 receptor antagonist for pain and respiratory disorders. The Indian company joins at least four other firms including Hydra Biosciences, Abbott and Janssen that are known to be working in the same ...
Quintiles to market Pharmaxis's cystic fibrosis product in Europe
31 August 2010
The Australian venture Pharmaxis has tapped the contract services company Quintiles to promote and sell its cystic fibrosis drug Bronchitol (mannitol) in Western Europe. An initial six-year agreement between the two firms will see Quintiles support ...
Baxter acquires alpha 1 -antitrypsin therapy and technology from Kamada
24 August 2010
Baxter is to pay the Israeli biopharmaceutical company Kamada $20 million upfront for the commercial rights to its liquid alpha 1 -proteinase inhibitor Glassia in the US, Australia, New Zealand and Canada. Glassia is the only approved liquid alpha ...
 
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Scrip Asia 100 - Influential Asia-Pacific pharma and biotech players
29 June 2010
Company Country HQ Principal officer Role Year established Workforce size Focus/area of specialty News flow Financial performance (FY 2009) Website ADImmune Taiwan Taipei Ignatius ...
Scrip Asia 100 - Manufacturing marvels
29 June 2010
Asia is home to countless companies specialising in pharmaceutical manufacturing. We think the following stand out from the crowd. Centre for Research and Production of Vaccines and Biology ...
 
Face-to-Face: Trophos - The French firm that hooked Actelion
23 July 2010
Actelion this week acquired the option to buy private company Trophos, with the final decision dependent on the success of the French firm's lead product olesoxime, which is in Phase III development ...
Xention looks to ion technology to jump start safer treatments
30 October 2009
While the patent cliff looms ever closer for big pharma, some smaller companies are not looking to untreated diseases to develop the new blockbuster but to conditions that are already catered for, ...
e-Therapeutics: leveraging unique drug discovery to secure partners
07 September 2009
As big pharma braces itself for the 2012 "winter of discontent", when several key drugs lose patent protection, these patent expiries also represent an opportunity for other firms. e-Therapeutics is ...
 
GLP-1 receptor agonists vie for diabetes market share
13 July 2010
After enjoying almost five years of exclusivity, Lilly/Amylin's first-in-class antidiabetic GLP-1 receptor analogue Byetta (exenatide) has started to feel competition nipping at its heels. Asher ...
Private investment round-up: June 2010 – UK industry fails to worry Top Track
02 August 2010
The UK's Sunday Times newspaper, in collaboration with FastTrack, last month published its annual Top Track 100 league table of the top 100 private companies in the UK with the greatest sales. ...
Private investment round-up: January 2010
16 February 2010
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies ...
 
Pharmacotherapy of pneumonia occurring in older patients
12 May 2009
The elderly population is characterized by several baseline conditions that increase the risk and modify the etiology of pneumonia. Immunosuppression caused by either concomitant morbidities or ...
Inhaled corticosteroids in COPD: systemic effects of a local therapy?
12 May 2009
Background: There are few data on the effects of inhaled corticosteroids on systemic inflammation in chronic obstructive pulmonary disease (COPD). Objective: Evaluation of the systemic ...
Toll-like receptors as therapeutic targets in cystic fibrosis
01 December 2008
Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm